Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility

Bioconjugate Chemistry

Volumn 12, Issue 3, 2001, Pages 414-420

  Niethammer, Andreas ^a   Gaedicke, Gerhard ^a   Lode, Holger N ^a   Wrasidlo, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; DRUG DELIVERY; SOLUBILITY;

ACTIVE CENTER; ANTITUMOUR ACTIVITY; HYDROXYL GROUPS; IN-VITRO; PACLITAXEL; PH-DEPENDENT; PRODRUGS; SIDE-CHAINS; SLOW RELEASE; WATER SOLUBILITIES;

CHEMOTHERAPY;

EID: 0034998446     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc000122g     Document Type: Article

References (37)

1. Rowinsky, E. K., and Donehower, R. C. (1995) Paclitaxel (taxol). N. Engl. J. Med. 332, 1004-14.
2. Chang, A. Y., Kim, K., Glick, J., Anderson, T., Karp, D., Johnson, D. (1993) Phase II study of taxol, merbarone, and piroxantrone in stage IV nonsmall-cell lung cancer: The Eastern Cooperative Oncology Group Results. J. Natl. Cancer. Inst. 85, 388-94.
3. Einzig, A. I., Gorowski, E., Sasloff, J., Wiernik, P. H. (1991) Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest. 9, 133-6.
4. Eisenhauer, E. A, ten Bokkel, H., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., et al. (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J. Clin. Oncol. 12, 2654-66.
5. Nabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., et al. (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 14, 1858-67.
6. Bonomi, P., Kim, K., Kusler, J., Johnson, D. (1997) Cisplatin/ etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology 11, 9-10.
7. Johnson, D., Arriagada, R., Barthelemy, N., Bonner, J., Bonomi, P., Enami, B., et al. (1997) Post-operative adjuvant therapy for non-small-cell lung cancer. Lung Cancer 17 Suppl 1, S23-S25
8. Bookman, M. A., McGuire, W. P., Kilpatrick, D., Keenan, E., Hogan, W. M., Johnson, S. W., et al. (1996) Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J. Clin. Oncol. 14, 1895-902.
9. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., McPhail, A. T. (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325-7.
10. Horwitz, S. B., Lothstein, L., Manfredi, J. J., Mellado, W., Parness, Roy S. N, et al. (1986) Taxol: mechanisms of action and resistance. Ann. N. Y. Acad. Sci. 466, 733-44.
11. Schiff, P. B., Fant, J., Horwitz, S. B. (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277, 665-7.
12. Manfredi, J. J., Fant, J., Horwitz, S. B. (1986) Taxol induces the formation of unusual arrays of cellular microtubules in colchicine-pretreated J774.2 cells. Eur. J. Cell. Biol. 42, 126-34.
13. Manfredi, J. J., Parness, J., Horwitz, S. B. (1982) Taxol binds to cellular microtubules. J. Cell. Biol. 94, 688-96.
14. Kumar, N. (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J. Biol. Chem. 256, 10435-41.
15. Jordan, M. A., Toso, R. J., Thrower, D., Wilson, L. (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. of Sci. U.S.A. 90, 9552-6.
16. Tishler, R. B., Schiff, P. B., Geard, C. R., Hall, E. J. (1992) Taxol: a novel radiation sensitizer. Int. J. Rad. Oncol. Biol. Phys. 22, 613-7.
17. Burkhart, C. A., Berman, J. W., Swindell, C. S., Horwitz, S. B. (1994) Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity. Cancer Res. 54, 5779-82.
18. Weiss, R. B., Donehower, R. C., Wiernik, P. H, Ohnuma, T., Gralla, R. J., Trump, D.L., et al. (1990) Hypersensitivity reactions from taxol. J. Clin. Oncol. 8, 1263-8.
19. Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Arbuck, S. G., Donehower, R.C. (1993) Clinical toxicities encountered with paclitaxel (Taxol). Sem. Oncol. 20, 1-15.
20. Huizing, M. T., Keung, A. C., Rosing, H., van dK, V., ten, Bokkel, H. W., et al. (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J. Clin. Oncol. 11, 2127-35.
21. Chaudhry, V., Rowinsky, E. K., Sartorius, S. E., Donehower, R. C., Cornblath, D. R. (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann. Neurol. 35, 304-11.
22. Rowinsky, E. K., Chaudhry, V., Cornblath, D. R., Donehower, R. C. (1993) Neurotoxicity of Taxol. J. Natl. Cancer. Inst. 85, 107-15.
23. Connors, T. A., and Knox, R. J. (1995) Prodrugs in cancer chemotherapy. Stem Cells 13, 501-11.
24. Reynolds, T. Y., Rockwell, S., Glazer, P. M. (1996) Genetic instability induced by the tumor microenvironment. Cancer Res. 56, 5754-7.
25. Boyer, M. J., and Tannock, I. F. (1992) Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. Cancer Res. 52, 4441-7.
26. Tomida, A., and Tsuruo, T. (1999) Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anti-Cancer Drug Design 14, 169-77.
27. Stratford, I. J., Adams, G. E., Bremner, J. C., Cole, S., Edwards, H. S., Robertson, N., et al. (1994) Manipulation and exploitation of the tumour environment for therapeutic benefit. Int. J. Rad. Biol. 65, 85-94.
28. Rockwell, S. (1992) Use of hypoxia-directed drugs in the therapy of solid tumors. Sem. Oncol. 19, 29-40.
29. Tannock, I. F., and Rotin, D. (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49 4373-84.
30. Kondo, T., Wada, K., Kawashima, M., Sato, Y., Yamauchi, M. (1994) High -sensitivity drug sensitivity testing. Oncology 51, 535-9.
31. Salmon, S. E. (1984) Development and applications of a human tumor colony assay for chemosensitivity testing. Rec. Res. Cancer Res. 94, 8-16.
32. Shoemaker, R. H., Wolpert-DeFilippes, M. K., Kern, D. H., Lieber, M. M., Makuch, R. W., Melnick, N. R., Miller, W. T., Salmon, S. E., Simon, R. M., Venditti, J. M., et al. (1985) Application of a human tumor colony-forming assay to new drug screening. Cancer Res. 45(5), 2145-53.
33. Nicolaou, K. C., Riemer, C., Kerr, M. A., Rideout, D., Wrasidlo, W. (1993) Design, synthesis and biological activity of protaxols. Nature 364, 464-6.
34. Tishler, R. B., Geard, C. R., Hall, E. J., Schiff, P. B. (1992) Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 52, 3495-7.
35. Lorenz, W, Reimann, H. J., Schmal, A., Dormann, P., Schwarz, B., Neugebauer, E., et al. (1977) Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 7, 63-7.
36. Choy, H. (1999) Taxanes in combined-modality therapy for solid tumors. Oncology 10, 23-38.
37. Donehower, R. C., Rowinsky, E. K. (1993) An overview of experience with taxol (paclitaxel) in the U.S.A. Cancer Treat. Rev. 19, 63-78.